Nuvectis Pharma (NASDAQ:NVCT) Releases Earnings Results, Misses Expectations By $0.78 EPS

Posted by Francis Steltz on Nov 6th, 2026

Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.78), Zacks reports.

Here are the key takeaways from Nuvectis Pharma’s conference call:

NXP100 has moved into commercial-stage development in China: Ciprocopan was approved for treatment-naive PNH patients after a Phase III study that management said outperformed Soliris on the primary and key secondary endpoints. A second Chinese PNH approval, for previously treated patients, is expected in Q1 2027.
The U.S. PNH pathway remains uncertain and may require new trials. FDA discussions are ongoing; although management said the agency’s questions about the China studies were addressed, it realistically expects at least one U.S. study and is preparing for possibilities ranging from one to two trials.
NXP100 could have opportunities beyond PNH, though evidence is still developing. Its China Phase II IgA nephropathy results included a 57% proteinuria reduction and an improvement in eGFR; a larger Phase III readout is expected around April or May 2027, and the company plans to pursue additional U.S. indications.
NXP200 showed encouraging early activity in glioma. Management cited a 40% response rate in the 20-patient high-grade glioma cohort, including three complete responses, and plans a U.S. IND by year-end with a Phase I-B study targeted for early 2027. Further China data across other tumor types is expected in the next few months.
Cash provides runway into the second half of 2029. Nuvectis ended the quarter with about $140 million, following a $150 million follow-on offering and roughly $37 million raised through its ATM; management says the funds should support multiple pipeline milestones.

Nuvectis Pharma Trading Up 12.8%

Shares of NVCT stock traded up $2.27 during trading hours on Friday, reaching $20.03. 48,170 shares of the company’s stock were exchanged, compared to its average volume of 174,479. Nuvectis Pharma has a 1 year low of $5.55 and a 1 year high of $29.27. The stock has a market cap of $653.86 million, a PE ratio of -10.63 and a beta of -0.21. The stock’s fifty day moving average price is $20.98 and its two-hundred day moving average price is $14.81.

Wall Street Analyst Weigh In

A number of research firms recently commented on NVCT. Cantor Fitzgerald started coverage on shares of Nuvectis Pharma in a research report on Monday, August 24th. They set an “overweight” rating for the company. HC Wainwright restated a “buy” rating and issued a $39.00 target price on shares of Nuvectis Pharma in a research note on Thursday, September 24th. Weiss Ratings raised shares of Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 21st. Lucid Cap Mkts raised shares of Nuvectis Pharma to a “strong-buy” rating in a report on Tuesday, September 1st. Finally, Loop Capital set a $40.00 price target on Nuvectis Pharma in a research report on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $36.25.

View Our Latest Analysis on NVCT

About Nuvectis Pharma

(Get Free Report)

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.